Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices.

Dhand R, Mahler DA, Carlin B, Hanania N, Ohar J, Pinto-Plata V, Shah T, Eubanks D, Braman SS.

Respir Care. 2018 Mar 20. pii: respcare.05715. doi: 10.4187/respcare.05715. [Epub ahead of print]

PMID:
29559537
2.

How does race/ethnicity influence pharmacological response to asthma therapies?

Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P.

Expert Opin Drug Metab Toxicol. 2018 Mar 12:1-12. doi: 10.1080/17425255.2018.1449833. [Epub ahead of print]

PMID:
29528249
3.

Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management.

Yohannes AM, Kaplan A, Hanania NA.

Cleve Clin J Med. 2018 Feb;85(2 Suppl 1):S11-S18. doi: 10.3949/ccjm.85.s1.03. No abstract available.

4.
5.

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.

Donohue JF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508. doi: 10.2147/COPD.S141729. eCollection 2018.

6.

Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.

Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M.

Drug Saf. 2018 Feb 6. doi: 10.1007/s40264-017-0636-9. [Epub ahead of print] Review.

PMID:
29411337
7.

Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions.

Hanania NA, Massanari M, Jain N.

Ann Allergy Asthma Immunol. 2018 Apr;120(4):414-418.e1. doi: 10.1016/j.anai.2018.01.031.

8.

Care pathways for the selection of a biologic in severe asthma.

Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, Domingo C, Hanania NA, Humbert M, Menzies Gow A, Phipatanakul W, Wahn U, Wechsler ME.

Eur Respir J. 2017 Dec 7;50(6). pii: 1701782. doi: 10.1183/13993003.01782-2017. Print 2017 Dec. No abstract available.

PMID:
29217605
9.

Trends in 30-day readmission rates after COPD hospitalization, 2006-2012.

Goto T, Faridi MK, Gibo K, Toh S, Hanania NA, Camargo CA Jr, Hasegawa K.

Respir Med. 2017 Sep;130:92-97. doi: 10.1016/j.rmed.2017.07.058. Epub 2017 Jul 26.

PMID:
29206640
10.

Procalcitonin in Chronic Obstructive Pulmonary Disease Exacerbations: Is It Ready for Primetime Use?

Narendra DK, Hanania NA.

Ann Am Thorac Soc. 2017 Dec;14(12):1757-1758. doi: 10.1513/AnnalsATS.201708-673ED. No abstract available.

PMID:
29192825
11.

Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts.

Parulekar AD, Martinez C, Tsai CL, Locantore N, Atik M, Yohannes AM, Kao CC, Al-Azzawi H, Mohsin A, Wise RA, Foreman MG, Demeo DL, Regan EA, Make BJ, Boriek AM, Wiener LE, Hanania NA.

J Am Med Dir Assoc. 2017 Dec 1;18(12):1063-1068. doi: 10.1016/j.jamda.2017.09.028.

PMID:
29169736
12.

Controversies and opportunities in severe asthma.

Humbert M, Busse W, Hanania NA.

Curr Opin Pulm Med. 2018 Jan;24(1):83-93. doi: 10.1097/MCP.0000000000000438.

PMID:
29059087
13.

The road to precision medicine in asthma: challenges and opportunities.

Hanania NA, Diamant Z.

Curr Opin Pulm Med. 2018 Jan;24(1):1-3. doi: 10.1097/MCP.0000000000000444. No abstract available.

PMID:
29045293
14.

Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.

Parulekar AD, Kao CC, Diamant Z, Hanania NA.

Curr Opin Pulm Med. 2018 Jan;24(1):50-55. doi: 10.1097/MCP.0000000000000436.

PMID:
29036019
15.

Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial.

Rogers L, Sugar EA, Blake K, Castro M, Dimango E, Hanania NA, Happel KI, Peters SP, Reibman J, Saams J, Teague WG, Wise RA, Holbrook JT; American Lung Association Airways Clinical Research Centers.

J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):633-643.e1. doi: 10.1016/j.jaip.2017.07.030. Epub 2017 Sep 30.

PMID:
28974349
16.

Predictive Biomarkers for Asthma Therapy.

Medrek SK, Parulekar AD, Hanania NA.

Curr Allergy Asthma Rep. 2017 Sep 19;17(10):69. doi: 10.1007/s11882-017-0739-5. Review.

PMID:
28929293
17.

Obesity modulates diaphragm curvature in subjects with and without COPD.

Boriek AM, Lopez MA, Velasco C, Bakir AA, Frolov A, Wynd S, Babb TG, Hanania NA, Hoffman EA, Sharafkhaneh A.

Am J Physiol Regul Integr Comp Physiol. 2017 Nov 1;313(5):R620-R629. doi: 10.1152/ajpregu.00173.2017. Epub 2017 Sep 13.

PMID:
28903915
18.

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

Monaco TJ, Hanania NA.

Expert Opin Emerg Drugs. 2017 Sep;22(3):285-299. doi: 10.1080/14728214.2017.1367382. Epub 2017 Sep 3. Review.

PMID:
28868931
19.

Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.

Casale TB, Chipps BE, Rosén K, Trzaskoma B, Haselkorn T, Omachi TA, Greenberg S, Hanania NA.

Allergy. 2018 Feb;73(2):490-497. doi: 10.1111/all.13302. Epub 2017 Sep 23.

20.

Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

Sethi S, Fogarty C, Hanania NA, Martinez FJ, Rennard S, Fries M, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Dwivedi S, Reisner C.

Chronic Obstr Pulm Dis. 2017 Apr 15;4(3):258. doi: 10.15326/jcopdf.4.3.2016.0158.

21.

Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

Sethi S, Fogarty C, Hanania NA, Martinez FJ, Rennard S, Fries M, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Dwivedi S, Reisner C.

Chronic Obstr Pulm Dis. 2016 Nov 17;4(1):21-33. doi: 10.15326/jcopdf.4.1.2016.0158. Erratum in: Chronic Obstr Pulm Dis. 2017 Apr 15;4(3):258.

22.

Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Wise RA, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA, Tashkin DP.

Chronic Obstr Pulm Dis. 2016 Nov 15;4(1):7-20. doi: 10.15326/jcopdf.4.1.2016.0141.

23.

Factors associated with depressive symptoms in uncontrolled asthmatics.

Mangold R, Salzman GA, Williams KB, Hanania NA.

J Asthma. 2018 May;55(5):555-560. doi: 10.1080/02770903.2017.1350968. Epub 2017 Sep 7.

PMID:
28759275
24.

Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.

Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG.

COPD. 2017 Oct;14(5):552-563. doi: 10.1080/15412555.2017.1347918. Epub 2017 Jul 28.

PMID:
28753070
25.

The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort.

Yohannes AM, Mülerová H, Lavoie K, Vestbo J, Rennard SI, Wouters E, Hanania NA.

J Am Med Dir Assoc. 2017 Nov 1;18(11):955-959.e6. doi: 10.1016/j.jamda.2017.05.024. Epub 2017 Jul 18.

PMID:
28733182
26.

Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial.

Kaminsky DA, Guntupalli KK, Lippmann J, Burns SM, Brock MA, Skelly J, DeSarno M, Pecott-Grimm H, Mohsin A, LaRock-McMahon C, Warren P, Whitney MC, Hanania NA.

J Altern Complement Med. 2017 Sep;23(9):696-704. doi: 10.1089/acm.2017.0102. Epub 2017 Jul 17.

PMID:
28714735
27.

Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.

Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C.

Respir Med. 2017 May;126:105-115. doi: 10.1016/j.rmed.2017.03.015. Epub 2017 Mar 12.

28.

Safety of inhaled long-acting anti-muscarinic agents in COPD.

Hanania NA, Lareau SC, Yawn BP.

Postgrad Med. 2017 Jun;129(5):500-512. doi: 10.1080/00325481.2017.1317575. Epub 2017 Apr 20. Review.

PMID:
28395575
29.

Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.

Biswas R, Hanania NA, Sabharwal A.

J Aerosol Med Pulm Drug Deliv. 2017 Aug;30(4):256-266. doi: 10.1089/jamp.2015.1278. Epub 2017 Feb 3.

PMID:
28157430
30.

Assessing Patient and Provider Perceptions of Factors Associated with Patient Engagement in Asthma Care.

Sapir T, Moreo KF, Greene LS, Simone LC, Carter JD, Mateka JJL, Hanania NA.

Ann Am Thorac Soc. 2017 May;14(5):659-666. doi: 10.1513/AnnalsATS.201608-602OC.

PMID:
28128966
31.

Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications.

Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, Hanania NA, Nair P.

Clin Exp Allergy. 2017 Feb;47(2):161-175. doi: 10.1111/cea.12880. Review.

PMID:
28036144
32.

Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma.

Medrek SK, Kao CC, Yang DH, Hanania NA, Parulekar AD.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1025-1031.e2. doi: 10.1016/j.jaip.2016.11.015. Epub 2016 Dec 22.

PMID:
28017627
33.

Generic medications in precision medicine in asthma.

Diamant Z, Hanania NA.

Curr Opin Pulm Med. 2017 Jan;23(1):1-2. No abstract available.

PMID:
27902500
34.

An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly.

Skloot GS, Busse PJ, Braman SS, Kovacs EJ, Dixon AE, Vaz Fragoso CA, Scichilone N, Prakash YS, Pabelick CM, Mathur SK, Hanania NA, Moore WC, Gibson PG, Zieman S, Ragless BB; ATS ad hoc Committee on Asthma in the Elderly.

Ann Am Thorac Soc. 2016 Nov;13(11):2064-2077.

35.

Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?

Parulekar AD, Diamant Z, Hanania NA.

Curr Opin Pulm Med. 2017 Jan;23(1):3-11. Review.

PMID:
27820746
36.

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG.

Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5.

PMID:
27616196
37.

Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD.

Lambert AA, Putcha N, Drummond MB, Boriek AM, Hanania NA, Kim V, Kinney GL, McDonald MN, Brigham EP, Wise RA, McCormack MC, Hansel NN; COPDGene Investigators.

Chest. 2017 Jan;151(1):68-77. doi: 10.1016/j.chest.2016.08.1432. Epub 2016 Aug 25.

38.

Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.

Dransfield MT, Kunisaki KM, Strand MJ, Anzueto A, Bhatt SP, Bowler RP, Criner GJ, Curtis JL, Hanania NA, Nath H, Putcha N, Roark SE, Wan ES, Washko GR, Wells JM, Wendt CH, Make BJ; COPDGene Investigators.

Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330. doi: 10.1164/rccm.201605-1014OC.

39.

Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.

Sun W, Kechris K, Jacobson S, Drummond MB, Hawkins GA, Yang J, Chen TH, Quibrera PM, Anderson W, Barr RG, Basta PV, Bleecker ER, Beaty T, Casaburi R, Castaldi P, Cho MH, Comellas A, Crapo JD, Criner G, Demeo D, Christenson SA, Couper DJ, Curtis JL, Doerschuk CM, Freeman CM, Gouskova NA, Han MK, Hanania NA, Hansel NN, Hersh CP, Hoffman EA, Kaner RJ, Kanner RE, Kleerup EC, Lutz S, Martinez FJ, Meyers DA, Peters SP, Regan EA, Rennard SI, Scholand MB, Silverman EK, Woodruff PG, O'Neal WK, Bowler RP; SPIROMICS Research Group; COPDGene Investigators.

PLoS Genet. 2016 Aug 17;12(8):e1006011. doi: 10.1371/journal.pgen.1006011. eCollection 2016 Aug.

40.

Characteristics and outcomes of older adults with long-standing versus late-onset asthma.

Herscher ML, Wisnivesky JP, Busse PJ, Hanania NA, Sheng T, Wolf MS, Federman AD.

J Asthma. 2017 Apr;54(3):223-229. doi: 10.1080/02770903.2016.1211141. Epub 2016 Jul 26.

PMID:
27459257
41.

Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.

Banerji D, Mahler DA, Hanania NA.

Expert Rev Respir Med. 2016 Jul;10(7):767-80. doi: 10.1080/17476348.2016.1190276. Epub 2016 May 30. Review.

PMID:
27223863
42.

Assessing biomarkers in a real-world severe asthma study (ARIETTA).

Buhl R, Korn S, Menzies-Gow A, Aubier M, Chapman KR, Canonica GW, Picado C, Martin N, Escobar RA, Korom S, Hanania NA.

Respir Med. 2016 Jun;115:7-12. doi: 10.1016/j.rmed.2016.04.001. Epub 2016 Apr 14.

43.

Lebrikizumab in the treatment of asthma.

Bujarski S, Parulekar AD, Hanania NA.

Expert Opin Biol Ther. 2016 May 10. [Epub ahead of print]

PMID:
27161908
44.

Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease.

Kim V, Zhao H, Boriek AM, Anzueto A, Soler X, Bhatt SP, Rennard SI, Wise R, Comellas A, Ramsdell JW, Kinney GL, Han MK, Martinez CH, Yen A, Black-Shinn J, Porszasz J, Criner GJ, Hanania NA, Sharafkhaneh A, Crapo JD, Make BJ, Silverman EK, Curtis JL; COPDGene Investigators.

Ann Am Thorac Soc. 2016 Jul;13(7):1016-25. doi: 10.1513/AnnalsATS.201512-800OC.

45.

The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation.

Yohannes AM, Dryden S, Hanania NA.

Chest. 2016 Jul;150(1):188-95. doi: 10.1016/j.chest.2016.02.658. Epub 2016 Mar 4.

PMID:
26953219
46.

Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort.

Yohannes AM, Müllerová H, Hanania NA, Lavoie K, Tal-Singer R, Vestbo J, Rennard SI, Wouters EF.

Chest. 2016 Apr;149(4):916-26. doi: 10.1016/j.chest.2015.10.081. Epub 2016 Jan 5.

PMID:
26836938
47.

Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts.

Martinez CH, Diaz AA, Parulekar AD, Rennard SI, Kanner RE, Hansel NN, Couper D, Holm KE, Hoth KF, Curtis JL, Martinez FJ, Hanania NA, Regan EA, Paine R 3rd, Cigolle CT, Han MK; COPDGene and SPIROMICS Investigators.

Chest. 2016 Apr;149(4):927-35. doi: 10.1016/j.chest.2015.11.025. Epub 2015 Dec 17.

48.

Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease.

Checkley W, Foreman MG, Bhatt SP, Dransfield MT, Han M, Hanania NA, Hansel NN, Regan EA, Wise RA; COPDGene Study Investigators.

Respir Med. 2016 Feb;111:30-8. doi: 10.1016/j.rmed.2015.11.004. Epub 2015 Nov 11.

49.

IgE-mediated asthma: New revelations and future insights.

Djukanovic R, Hanania N, Busse W, Price D.

Respir Med. 2016 Mar;112:128-9. doi: 10.1016/j.rmed.2015.10.013. Epub 2015 Oct 30.

50.

Role of T2 inflammation biomarkers in severe asthma.

Parulekar AD, Diamant Z, Hanania NA.

Curr Opin Pulm Med. 2016 Jan;22(1):59-68. doi: 10.1097/MCP.0000000000000231. Review.

PMID:
26574724

Supplemental Content

Loading ...
Support Center